Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PKM | P14618 | 3/20 | 0.54 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.54 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.54 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.53 |
| ▸ | POLB | P06746 | 1/20 | 0.53 |
| ▸ | HTT | P42858 | 1/20 | 0.53 |
| ▸ | TSHR | P16473 | 2/20 | 0.51 |
| ▸ | NPC1 | O15118 | 1/20 | 0.50 |
| ▸ | RAB9A | P51151 | 1/20 | 0.50 |
| ▸ | MDM2 | Q00987 | 1/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.49 |
| ▸ | LMNA | P02545 | 1/20 | 0.49 |
| ▸ | GAA | P10253 | 1/20 | 0.49 |
| ▸ | MEN1 | O00255 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23997508 | 0.94 | PKM (0.60) | PKMCYP2C19CYP3A4ALDH1A1POLB | |
| SCHEMBL4108239 | 0.90 | ALDH1A1 (0.67) | PKMCYP2C19CYP3A4ALDH1A1POLB | |
| SCHEMBL7464192 | 0.89 | CYP3A4 (0.64) | PKMCYP2C19CYP3A4ALDH1A1POLB | |
| SCHEMBL15466863 | 0.88 | PKM (0.49) | PKMCYP2C19CYP3A4ALDH1A1POLB | |
| SCHEMBL15471055 | 0.88 | PKM (0.49) | PKMCYP2C19CYP3A4ALDH1A1POLB | |
| SCHEMBL15466862 | 0.88 | PKM (0.49) | PKMCYP2C19CYP3A4ALDH1A1POLB | |
| SCHEMBL2474562 | 0.85 | ALDH1A1 (0.62) | PKMALDH1A1POLBHTTNPC1 | |
| SCHEMBL12587132 | 0.85 | CYP3A4 (0.76) | PKMCYP2C19CYP3A4ALDH1A1POLB | |
| SCHEMBL21510197 | 0.83 | PKM (0.54) | PKMCYP2C19ALDH1A1POLBHTT | |
| SCHEMBL8680069 | 0.82 | CD4 (0.61) | PKMCYP2C19CYP3A4ALDH1A1POLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20190321313-A1 | BENZENESULFONAMIDE DERIVATIVES AND METHOD FOR TREATING CANCER | Gongwin Biopharm Holdings Co., Ltd. | 2019-10-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190321313-A1 | BENZENESULFONAMIDE DERIVATIVES AND METHOD FOR TREATING CANCER | ARSA, ABCB1, ABCG2 | PKM 1749/4885CYP2C19 70/4885CYP3A4 34/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.